The Learner Notification
for ISHLT’s 43rd
ISHLT Annual Meeting & Scientific Sessions is now available. You can download the document using the button below or find it in the ISHLT2023 mobile app
by tapping “CME Information
” in the menu.
The International Society for Heart and Lung Transplantation (ISHLT) expects that all of its CME programs will adhere to the Accreditation Council for Continuing Medical Education’s (ACCME) content validation value statements: “Specifically, all the recommendations involving clinical medicine in a CME activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.” The ISHLT expects that the content or format of CME activities and related materials will promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The ISHLT must collect financial disclosure information from all planners, faculty, and others in control of educational content about all their financial relationships with ineligible companies within the prior 24 months. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of the relationship to the education.
The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in the care and treatment of patients with advanced heart or lung disease.
The audience for this program includes physicians, surgeons, scientists, pharmacists, nurses, transplant coordinators and other allied health and social science professionals engaged in the management and treatment of patients with advanced heart or lung disease, basic science or clinical research related to these fields, or other specialties which cause them to become involved in the treatment of patients with advanced heart or lung disease.
- ► Discuss the latest information and approaches regarding transplant research, surgical techniques, medical therapies, donor management and patient management for the treatment of patients suffering from advanced heart and lung disease.
- ► Apply state-of-the art treatment approaches, risk factors, risk management approaches, donor selection and preservation methods, patient selection criteria, disease prevention strategies, outcome implications and psychosocial management strategies for patients with advanced heart and lung failure.
- ► Evaluate emerging technologies, medical advances and the clinical applications of basic science models of advanced heart and lung disease management and prevention.
Educational Gap, Learning Needs, and Expected Results
Clinical Practice Gap
Tens of thousands of patients with advanced heart and lung failure may be eligible to be considered as potential candidates for heart or lung transplant every year when medical and surgical therapies have been exhausted (1) The limiting issue to all of thoracic transplant continues to be the limited availability of donors leading to deaths on both the heart and lung transplant waiting lists. Although surgical techniques, along with donor and recipient selection have improved but short-term survival is still not 100% at one year. Approximately 15% of patients receiving a thoracic organ transplant in the US die within the first year. In fact ,22% of patients receiving a ventricular assist device die within the first year. Median long-term survival is 11 years for heart transplants recipients and only 8.3 years for lung transplant recipients but is not routinely several decades in duration as with abdominal solid organ transplant. The vast majority of patients receiving a transplant or a ventricular assist device experience life-threatening complications throughout their lives. Decisions about transplantation versus medical therapy and about treating patients with end stage heart and lung disease are truly life and death decisions. Physicians do not have access updated information about current practices, emerging technologies, and medical advances related to heart and lung transplantation and advanced heart and lung disease management and to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.
Underlying Educational Need
Education is needed to convey the knowledge and practices that can lead to better outcomes for these very ill patients. Such knowledge and practices include medical therapy and management of patients suffering from advanced heart and lung disease; selection, management, and allocation of donor organs, selection, and management of donor organs; surgical techniques; patient selection and management; diagnosis and management of post-transplant/implant complications and diseases; management of immunosuppressive regimens; management of psychosocial issues. Because of the rapid advances in patient health care in general and advanced heart and lung disease management in particular, professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in the field. This meeting is designed to address their needs.
Designed to Change
This activity is designed to improve competence and professional performance in the areas of understanding the latest information and approaches regarding transplant research, surgical techniques, medical therapies, donor selection and management and patient management for the treatment of patients suffering from end-stage heart and lung disease. Participants will have improved competence and professional performance in the areas of understanding the state-of-the-art treatment approaches, risk factors, risk management approaches, patient selection criteria, disease prevention strategies, outcome implications and psychosocial management strategies for patients with end-stage heart and lung failure. Participants will also have improved competence and professional performance in the areas of understanding emerging technologies, medical advances, and the clinical applications of basic science models of end-stage heart and lung disease management and prevention.
Accreditation Statement –
International Society for Heart & Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement –
ISHLT designates this live activity for a maximum of 24.00 AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
As a designated Approved Provider by the American Board for Transplant Certification (ABTC), the International Society for Heart and Lung Transplantation grants up to 24 Category 1 Continuing Education Points for Transplant Coordinators (CEPTCs) for this offering. CEPTC Approval Number: 221-29.
Nurses and Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and International Society for Heart & Lung Transplantation. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) – Credit Designation Statement –
Amedco LLC designates this activity for a maximum of 24.00 ANCC contact hours.
Pharmacists (ACPE) – Credit Designation Statement –
Amedco LLC designates this activity for a maximum of 24.00 knowledge-based CPE contact hours.
NOTE TO PHARMACISTS: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
The American Medical Association has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™
ACCME / AMA PRA Category 1 Credits™
carry reciprocity with EACCME member countries and most international licensing bodies for physicians, with some exceptions. Physicians should check with their country/board for eligibility.
The UEMS-EACCME and the AMA has a signed agreement of mutual recognition of CME credits between Europe and USA for live and e-learning activities. A list of active agreements can be found here https://eaccme.uems.eu/Agreements.aspx
The EACCME® has signed agreements with the following countries: Austria, Armenia, Belgium, Bulgaria, Croatia, Cyprus, Finland, Georgia, Greece, Hungary, Ireland, Regione Lombardia, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Tunisia, Turkey, United Kingdom